clinical trial · NCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals, LLC·phase1·recruiting·n = 60
Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate CancerDCC-2812
brief summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
started
Aug 27, 2025
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Apr 21, 2026
official title
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol